MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis. - Spec, Andrej; Pullman, John; Thompson, George R; Powderly, William G; Tobin, Ellis H; Vazquez, Jose; Wring, Stephen A; Angulo, David; Helou, Silvia; Pappas, Peter G; Group, Mycoses Study; Mycoses Study Group (Journal of Antimicrobial Chemotherapy (JAC), 2019)